Bonus Biogroup - Asset Resilience Ratio

Latest as of March 2024: 10.04%

Bonus Biogroup (BONS) has an Asset Resilience Ratio of 10.04% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

ILA3.90 Million

≈ $10.45K USD Cash + Short-term Investments

Total Assets

ILA38.85 Million

≈ $104.16K USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2008–2015)

This chart shows how Bonus Biogroup's Asset Resilience Ratio has changed over time. Check BONS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Bonus Biogroup's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bonus Biogroup stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA3.90 Million	10.04%
Total Liquid Assets	ILA3.90 Million	10.04%

Asset Resilience Insights

Moderate Liquidity: Bonus Biogroup has 10.04% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Bonus Biogroup Industry Peers by Asset Resilience Ratio

Compare Bonus Biogroup's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	5.66%
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Abivax SA PA:ABVX	Biotechnology	2.34%
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	Biotechnology	5.07%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
REMEGEN CO. LTD YC 1 F:REG	Biotechnology	16.77%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Bonus Biogroup (2008–2015)

The table below shows the annual Asset Resilience Ratio data for Bonus Biogroup.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2015-12-31	1.88%	ILA108.00K ≈ $289.54	ILA5.76 Million ≈ $15.43K	-20.23pp
2014-12-31	22.11%	ILA1.00 Million ≈ $2.68K	ILA4.52 Million ≈ $12.13K	-42.61pp
2013-12-31	64.72%	ILA5.28 Million ≈ $14.15K	ILA8.16 Million ≈ $21.87K	-12.06pp
2012-12-31	76.78%	ILA6.80 Million ≈ $18.22K	ILA8.85 Million ≈ $23.73K	+71.44pp
2010-12-31	5.34%	ILA324.00K ≈ $868.63	ILA6.07 Million ≈ $16.28K	+0.43pp
2009-12-31	4.90%	ILA2.42 Million ≈ $6.49K	ILA49.39 Million ≈ $132.40K	+0.78pp
2008-12-31	4.13%	ILA2.10 Million ≈ $5.62K	ILA50.81 Million ≈ $136.21K	--

pp = percentage points

About Bonus Biogroup

TA:BONS Israel Biotechnology

Market Cap

$86.42 Million

ILA32.23 Billion ILA

Market Cap Rank

#19678 Global

#256 in Israel

Share Price

ILA27.60

Change (1 day)

-1.08%

52-Week Range

ILA21.10 - ILA58.50

All Time High

ILA171.00